SuperworthClearPoint Neuro profit margin CLPT
Gross, operating and net profit as a share of revenue over the last twelve months, from 2013.
- Net margin, 12 months
- −81.8%
- Operating margin, 12 months
- −73.4%
- Net margin on a year earlier
- −15.6 pts
- Peer median
- 6.5%
Over the twelve months to Jun 30, 2026, ClearPoint Neuro kept −81.8% of its revenue as net profit, with an operating margin of −73.4% and a gross margin of 62.6%.
Five years earlier its net margin was −63.7%.
The median for 10 medical instruments and supplies stocks of a similar size is 6.5%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −69.1% | −65.4% | 61.4% |
| FY2024 | −60.3% | −62.9% | 60.9% |
| FY2023 | −92.2% | −93.7% | 56.8% |
| FY2022 | −80.0% | −79.5% | 65.8% |
| FY2021 | −88.4% | −82.1% | 68.2% |
| FY2020 | −52.9% | −48.5% | 71.1% |
| FY2019 | −49.4% | −41.0% | 64.9% |
| FY2018 | −83.8% | −71.4% | 66.9% |
| FY2017 | −97.1% | −85.9% | 60.7% |
| FY2016 | n/a | n/a | 54.0% |
| FY2015 | n/a | n/a | 56.7% |
| FY2014 | n/a | n/a | 46.5% |
| FY2013 | n/a | n/a | 63.8% |
| FY2012 | n/a | −61.9% | 89.0% |
| FY2011 | n/a | n/a | 82.8% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −81.8% | −15.6 pts | −73.4% | |
| Q1 FY26 | −71.6% | −7.1 pts | −65.2% | |
| Q4 FY25 | −69.1% | −8.8 pts | −65.4% | |
| Q3 FY25 | −67.4% | −7.8 pts | −66.3% | |
| Q2 FY25 | −66.2% | −2.1 pts | −67.4% | |
| Q1 FY25 | −64.5% | +14.3 pts | −67.3% | |
| Q4 FY24 | −60.3% | +32.0 pts | −62.9% | |
| Q3 FY24 | −59.6% | +38.3 pts | −61.8% | |
| Q2 FY24 | −64.1% | +31.9 pts | −66.1% | |
| Q1 FY24 | −78.8% | +7.5 pts | −80.1% | |
| Q4 FY23 | −92.2% | −12.2 pts | −93.7% | |
| Q3 FY23 | −97.9% | −15.5 pts | −99.5% |
Against its peers
Companies in Medical - Instruments & Supplies nearest ClearPoint Neuro's size, closest first, today.
| Company | Profit margin |
|---|---|
| CLPTClearPoint Neuro | −81.8% |
| INFUInfuSystem | 6.0% |
| UTMDUtah Medical Products | 29.0% |
| EMBCEmbecta | 8.6% |
| PDEXPro DEX | 17.6% |
| TCMDTactile Systems Technology | 7.1% |
| MDXGMimedx | 1.8% |
| MOVMovado | 6.0% |
| KEQUKewaunee Scientific | 3.0% |
| IRMDIradimed | 26.7% |
| STAAStaar Surgical | 1.1% |
| Peer median | 6.5% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on ClearPoint Neuro
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.